Arvinas, Inc. (ARVN)
Largest Insider Buys in Sector
ARVN Stock Price History Chart
ARVN Stock Performance
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of …
Insider Activity of Arvinas, Inc.
Over the last 12 months, insiders at Arvinas, Inc. have bought $0 and sold $484,521 worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $25.51M and sold $29.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 285,714 shares for transaction amount of $20M was made by Ratcliffe Liam (director) on 2020‑12‑18.
List of Insider Buy and Sell Transactions, Arvinas, Inc.
| 2024-02-23 | Sale | President and CEO | 5,196 0.0095% | $47.05 | $244,472 | -38.30% | ||
| 2024-02-23 | Sale | Chief Financial Officer | 1,702 0.0031% | $47.05 | $80,079 | -38.30% | ||
| 2024-02-23 | Sale | Chief Scientific Officer | 1,701 0.0031% | $47.05 | $80,032 | -38.30% | ||
| 2024-02-23 | Sale | Chief Medical Officer | 1,699 0.0031% | $47.05 | $79,938 | -38.30% | ||
| 2023-08-11 | Sale | Chief Medical Officer | 1,324 0.0024% | $24.39 | $32,289 | +27.75% | ||
| 2023-03-01 | Sale | President and CEO | 5,878 0.0107% | $29.53 | $173,577 | -14.21% | ||
| 2023-03-01 | Sale | Chief Financial Officer | 1,745 0.0032% | $29.53 | $51,530 | -14.21% | ||
| 2023-03-01 | Sale | Chief Scientific Officer | 1,051 0.0019% | $29.53 | $31,036 | -14.21% | ||
| 2022-08-12 | Sale | Chief Medical Officer | 1,258 0.0024% | $54.84 | $68,994 | -40.58% | ||
| 2022-04-14 | Sale | 10,754 0.0202% | $67.03 | $720,888 | -36.79% | |||
| 2022-03-11 | Sale | Chief Financial Officer | 15,000 0.029% | $70.00 | $1.05M | -36.08% | ||
| 2022-03-04 | Sale | President and CEO | 6,024 0.0113% | $63.94 | $385,175 | -31.76% | ||
| 2022-03-04 | Sale | Chief Financial Officer | 1,593 0.003% | $63.94 | $101,856 | -31.76% | ||
| 2022-03-04 | Sale | Chief Scientific Officer | 869 0.0016% | $63.94 | $55,564 | -31.76% | ||
| 2022-02-15 | Sale | Chief Scientific Officer | 20,000 0.0378% | $73.02 | $1.46M | -38.58% | ||
| 2022-01-14 | Sale | director | 20,960 0.0385% | $65.55 | $1.37M | -29.61% | ||
| 2021-12-30 | Sale | Chief Medical Officer | 20,000 0.0382% | $80.61 | $1.61M | -38.61% | ||
| 2021-12-17 | Sale | Chief Financial Officer | 15,000 0.0271% | $70.00 | $1.05M | -32.08% | ||
| 2021-12-16 | Sale | director | 85,705 0.1636% | $69.36 | $5.94M | -27.43% | ||
| 2021-12-15 | Sale | director | 113,536 0.2076% | $66.81 | $7.58M | -27.70% |
Insider Historical Profitability
| Houston John G | President and CEO | 1036681 1.5087% | $28.19 | 1 | 10 | +24.92% |
| Cassidy Sean A | Chief Financial Officer | 181916 0.2647% | $28.19 | 1 | 13 | +24.92% |
| Taylor Ian | Chief Scientific Officer | 147522 0.2147% | $28.19 | 1 | 12 | +66.46% |
| RA CAPITAL MANAGEMENT, LLC | 3138412 4.5674% | $28.19 | 1 | 0 | +24.92% | |
| SHANNON TIMOTHY M | director | 1653128 2.4058% | $28.19 | 5 | 11 | +35.38% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $277.67M | 9.83 | 6.73M | 0% | +$0 | 1.95 | |
| The Vanguard Group | $260.05M | 9.21 | 6.3M | +29.85% | +$59.78M | 0.01 | |
| BlackRock | $226.8M | 8.03 | 5.49M | +2.6% | +$5.75M | 0.01 | |
| T. Rowe Price | $180.33M | 6.38 | 4.37M | +13.99% | +$22.14M | 0.02 | |
| RTW Investments, LP | $136.14M | 4.82 | 3.3M | -21.73% | -$37.8M | 2.04 |